MX2010007083A - Combinacion anti-retroviral. - Google Patents

Combinacion anti-retroviral.

Info

Publication number
MX2010007083A
MX2010007083A MX2010007083A MX2010007083A MX2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A MX 2010007083 A MX2010007083 A MX 2010007083A
Authority
MX
Mexico
Prior art keywords
ester
retroviral combination
pharmaceutically acceptable
acceptable salt
retroviral
Prior art date
Application number
MX2010007083A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MX2010007083A publication Critical patent/MX2010007083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe una composición farmacéutica que comprende una forma de dosis unitaria sólida que incluye: (i) ritonavir o una sal farmacéuticamente aceptable y el éster del mismo; (ii) darunavir o una sal farmacéuticamente aceptable y el éster del mismo.
MX2010007083A 2007-12-24 2008-12-24 Combinacion anti-retroviral. MX2010007083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24
PCT/GB2008/004291 WO2009081174A2 (en) 2007-12-24 2008-12-24 Anti - retroviral combination

Publications (1)

Publication Number Publication Date
MX2010007083A true MX2010007083A (es) 2010-10-20

Family

ID=54289250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007083A MX2010007083A (es) 2007-12-24 2008-12-24 Combinacion anti-retroviral.

Country Status (20)

Country Link
US (1) US9339470B2 (es)
EP (2) EP2242482B1 (es)
JP (2) JP2011507940A (es)
CN (2) CN101925350B (es)
AP (2) AP2013007064A0 (es)
AT (1) ATE555778T1 (es)
AU (1) AU2008339633A1 (es)
BR (1) BRPI0819534A2 (es)
CA (1) CA2710605C (es)
DK (1) DK2242482T3 (es)
ES (2) ES2674730T3 (es)
GT (1) GT200800303A (es)
HK (1) HK1149905A1 (es)
JO (2) JO2814B1 (es)
MX (1) MX2010007083A (es)
PA (1) PA8809601A1 (es)
PE (2) PE20140926A1 (es)
RU (2) RU2531089C2 (es)
WO (1) WO2009081174A2 (es)
ZA (1) ZA201004505B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
US8829208B2 (en) 2010-01-28 2014-09-09 Mapi Pharma Ltd. Process for the preparation of darunavir and darunavir intermediates
US20130317040A1 (en) * 2010-12-22 2013-11-28 The Feinstein Institute Of Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
CA2837539C (en) * 2011-07-07 2021-08-10 Janssen R&D Ireland Darunavir formulations
ES2651212T3 (es) * 2011-07-07 2018-01-25 Janssen Sciences Ireland Uc Formulaciones combinadas de darunavir
RU2014148964A (ru) * 2012-05-03 2016-06-27 Сипла Лимитед Антиретровирусная композиция
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3496718A4 (en) * 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
AU4810490A (en) 1988-12-20 1990-07-10 Mawzones Developments Limited Focussing device for a microwave antenna
AU641375B2 (en) 1988-12-20 1993-09-23 Clarity Technologies Incorporated Synthetic HIV-like peptides, their compositions and uses
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
DE69332616T2 (de) 1992-12-29 2003-11-06 Abbott Laboratories, Abbott Park Hemmer der retroviralen Protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AU2005261701A1 (en) 2004-07-08 2006-01-19 Janssen R&D Ireland Combination of anti-HIV reverse transcriptase and protease inhibitors
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AP2008004533A0 (en) 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral

Also Published As

Publication number Publication date
JO3376B1 (ar) 2019-03-13
JP2011507940A (ja) 2011-03-10
RU2675831C2 (ru) 2018-12-25
WO2009081174A3 (en) 2009-08-27
WO2009081174A2 (en) 2009-07-02
RU2014111723A (ru) 2015-10-10
PE20091530A1 (es) 2009-09-25
RU2010131006A (ru) 2012-02-10
EP2242482A2 (en) 2010-10-27
DK2242482T3 (da) 2012-08-06
CA2710605C (en) 2017-05-02
JP2015007071A (ja) 2015-01-15
EP2505193A1 (en) 2012-10-03
RU2531089C2 (ru) 2014-10-20
AU2008339633A1 (en) 2009-07-02
US9339470B2 (en) 2016-05-17
CN101925350B (zh) 2014-04-30
BRPI0819534A2 (pt) 2015-05-26
PE20140926A1 (es) 2014-08-06
CA2710605A1 (en) 2009-07-02
AP2013007064A0 (en) 2013-08-31
GT200800303A (es) 2009-09-18
AP2010005325A0 (en) 2010-08-31
JO2814B1 (en) 2014-09-15
EP2242482B1 (en) 2012-05-02
ES2674730T3 (es) 2018-07-03
ZA201004505B (en) 2013-05-29
CN101925350A (zh) 2010-12-22
ATE555778T1 (de) 2012-05-15
HK1149905A1 (en) 2011-10-21
AP2855A (en) 2014-02-28
CN103638032A (zh) 2014-03-19
ES2385819T3 (es) 2012-08-01
EP2505193B1 (en) 2018-05-02
US20110008429A1 (en) 2011-01-13
PA8809601A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2010007083A (es) Combinacion anti-retroviral.
PT2046298T (pt) Forma de dosagem farmacêutica contendo uma composição solubilizante farmaceuticamente aceitável
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL185390A (en) A solid dosage form
AU2008347158A8 (en) Oral pharmaceutical dosage forms
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
MY143351A (en) Solid orally administerable pharmaceutical dosage forms with rapid active principle release
SI2399580T1 (sl) Farmacevtske odmerne oblike
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2009011588A (es) Formas de dosificacion solidas que comprenden tadalafil.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
ZA200704915B (en) Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions
EP1862183A4 (en) PHARMACEUTICAL COMPOSITION WITH HEAVY WATER-SOLUBLE MEDICAMENT
IL178067A0 (en) Pharmaceutical dosage forms and compositions
AU2012280198A8 (en) Darunavir combination formulations
HK1112575A1 (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
EP1937414A4 (en) PHARMACEUTICAL FORM FOR ORAL MUCOUSES
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
ZA200706706B (en) Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
EP1948199A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS
TW200833375A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration